Nyrada has received supportive written feedback from the US FDA on its proposed pathway for taking Xolatryp into a US Phase IIa heart-attack trial. The regulator identified no major issues, but additional information and stability data are still required before the planned IND submission in the first half of 2027.
- FDA found no major issues with Nyrada’s proposed Xolatryp development pathway
- Nonclinical safety package appears sufficient to support the planned Phase IIa study
- FDA accepted Phase IIa progression before completion of a thorough QT/QTc study
- Additional information and stability data are required for the IND submission
- US IND remains targeted for the first half of calendar 2027
FDA Finds No Major Issues With Xolatryp Pathway
Nyrada Inc. (ASX:NYR) has cleared a meaningful regulatory checkpoint for Xolatryp, receiving written US FDA feedback that supports its proposed development pathway for a Phase IIa heart-attack study. The response covered the drug candidate’s manufacturing information, nonclinical data, cardiac safety package and planned clinical design, with no major issues identified.
The feedback is not an IND clearance or evidence that Xolatryp works in patients. It does, however, reduce some of the uncertainty around what Nyrada must provide to open a US trial of its cardioprotection program, which is designed to reduce reperfusion injury in STEMI patients undergoing primary PCI.
PROTECT-MI Moves Toward US Expansion
The FDA indicated that Nyrada’s completed nonclinical safety program appears sufficient in scope to support the proposed Phase IIa study, subject to additional information being included in the final IND. It also offered guidance on using existing nonclinical data in later development, which may reduce the need for further toxicology work.
The response follows the first Xolatryp patient dosing reported earlier this year, when Nyrada began its Phase IIa PROTECT-MI trial in Australia. The company’s recent AU$12 million placement was intended to advance Xolatryp clinical programs, while Nyrada now says recruitment into PROTECT-MI remains its immediate priority.
Cardiac Safety and Manufacturing Packages Accepted in Principle
On the clinical side, the FDA agreed in principle with the proposed patient population, safety monitoring and endpoint framework for a Phase IIa trial. It also accepted progression before completion of a thorough QT/QTc study, relying on the available Phase I cardiac safety data and planned ECG and telemetry monitoring.
The regulator considered the proposed testing scope for the drug substance and product appropriate to support an IND submission, although it will assess the final specifications during its review and has requested more stability information. Those requirements leave work to complete, but the company remains targeted to lodge the US IND during the first half of calendar 2027.
Fast Track Possibility Remains Conditional
The FDA acknowledged the seriousness of STEMI and indicated that a future Fast Track Designation request may be reasonable if a later Phase III trial evaluates clinical endpoints reflecting serious aspects of the condition. That is a possible regulatory advantage rather than a current designation: any request would depend on later clinical development and the endpoints ultimately selected.
Bottom Line?
The next hard test is execution: completing the requested IND material while recruiting PROTECT-MI and demonstrating whether Xolatryp’s encouraging development pathway translates into patient data.
Questions in the middle?
- Can Nyrada complete the additional IND information and stability work within its first-half 2027 timetable?
- How quickly can PROTECT-MI recruit enough STEMI patients to produce interpretable Phase IIa safety and preliminary efficacy data?
- Will the clinical results ultimately support a future Fast Track request and a broader Phase III program?